← Back to Search

Hormone Therapy

Bevacizumab + Hormone & Radiation Therapies for Prostate Cancer

Phase 2
Waitlist Available
Research Sponsored by Virginia Mason Hospital/Medical Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
High-risk, locally advanced disease meeting specific criteria (Gleason score 8-10, or Prostate-specific antigen > 20 ng/dL AND Gleason score 7, or T2a disease with specific biopsy requirements)
Histologically confirmed adenocarcinoma of the prostate
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights

Study Summary

This trial is studying bevacizumab in combination with hormone therapy and radiation therapy to see how well it works in treating patients with high-risk locally advanced prostate cancer.

Who is the study for?
Men with high-risk, locally advanced prostate cancer can join this trial. They should have a PSA >20 ng/dL, Gleason score of 7-10, and no metastatic disease. Participants need to be relatively healthy (ECOG 0-2), with adequate blood counts and organ function, controlled blood pressure, no recent heart attacks or strokes, and not on prior hormone therapy for prostate cancer.Check my eligibility
What is being tested?
The study is testing the combination of Bevacizumab (a monoclonal antibody that blocks tumor growth), hormone therapy (drugs like goserelin and bicalutamide that stop production of male hormones), and radiation therapy to see if they work better together in treating patients with aggressive prostate cancer.See study design
What are the potential side effects?
Bevacizumab may cause issues like high blood pressure, bleeding or clotting problems, headaches or vision changes due to brain swelling. Hormone therapy might lead to hot flashes, sexual dysfunction or bone thinning. Radiation could result in skin irritation at the treatment site or fatigue.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
My prostate cancer is high-risk with specific Gleason scores or PSA levels.
Select...
My prostate cancer diagnosis was confirmed through a tissue examination.
Select...
I can take care of myself and am up and about more than half of my waking hours.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Efficacy
Safety

Find a Location

Who is running the clinical trial?

Virginia Mason Hospital/Medical CenterLead Sponsor
20 Previous Clinical Trials
3,408 Total Patients Enrolled
2 Trials studying Prostate Cancer
317 Patients Enrolled for Prostate Cancer
Jacqueline Vuky, MDStudy ChairVirginia Mason Hospital/Medical Center
3 Previous Clinical Trials
53 Total Patients Enrolled
3 Trials studying Prostate Cancer
53 Patients Enrolled for Prostate Cancer

Media Library

Bicalutamide (Hormone Therapy) Clinical Trial Eligibility Overview. Trial Name: NCT00348998 — Phase 2
Prostate Cancer Research Study Groups:
Prostate Cancer Clinical Trial 2023: Bicalutamide Highlights & Side Effects. Trial Name: NCT00348998 — Phase 2
Bicalutamide (Hormone Therapy) 2023 Treatment Timeline for Medical Study. Trial Name: NCT00348998 — Phase 2

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Has the FDA granted authorization for this treatment?

"Our team at Power assigned this new treatment a safety rating of 2, which reflects the limited amount of data that has been collected in Phase 2 trials with regards to its efficacy."

Answered by AI

Is this study actively seeking volunteers at present?

"This trial has already reached its maximum number of participants, as evidenced by the last update to clinicaltrials.gov on November 5th 2013; however there are 1321 other medical studies currently recruiting patients at this time."

Answered by AI
~1 spots leftby Mar 2025